igf-1 lr3 human study IGF1 | IGF1 Peptide | Recombinant LR3-IGF-I (Receptor Grade), Human -

With patient safety at the helm, there is an unequivocal need to optimize the drug formulation and perhaps reconfigure its dosing paradigms to circumvent such grave outcomes

During this meeting, the advisory committee will: Review available safety and efficacy data for BPC-157, including preclinical studies and any available clinical evidence Consider public comments submitted by patients, practitioners, and industry stakeholders Evaluate the clinical need for compounded BPC-157 and the patient populations that would benefit Assess the compounding quality considerations specific to peptide formulations Issue a recommendation to the FDA on whether BPC-157 should be included on the 503A compounding list Possible outcomes include: Positive recommendation: PCAC advises the FDA to add BPC-157 to the 503A list, clearing the way for legal compounding nationwide

Funding This study was supported by Jiangsu Province Elderly Health Research Project (LKZ2024012) and Jiangsu Provincial Science and Technology Development Plan for Traditional Chinese Medicine (MS2022148)

10.1183/09031936.00003309 73 GBD Chronic Respiratory Disease Collaborators (2020)